SOUTH SAN FRANCISCO, Calif., June 09, 2016 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the opening of a new customer inspiration center in Markham, Ontario, Canada. Providing researchers with firsthand experience on the Helios™ system, the latest mass cytometry instrument using CyTOF® technology, the customer inspiration center will be open to investigators around the world seeking to incorporate mass cytometry in their own research laboratories.
Mass cytometry uniquely enables high-parameter analysis of millions of cells at single-cell resolution. With a growing list of hundreds of peer-reviewed publications, mass cytometry has been instrumental in revealing new insights in health and disease. Transcending the inherent technical limitations of flow cytometry, researchers can more efficiently design and implement highly multiplexed antibody panels across a range of cell surface and intracellular protein markers. With over 600 pre-conjugated antibodies available and the flexibility to conjugate new antibodies to suit the needs of each experimental study, mass cytometry is fast becoming a standard method to deeply profile precious translational and clinical research samples across important disease areas including cancer, immunology, and cancer immunotherapy.
“Our new mass cytometry customer inspiration center was developed in response to increasing interest from our customers,” said Dmitry Bandura, Vice President of Research and Development at Fluidigm. “While our new center will initially enable demonstrations of mass cytometry, we plan to expand this center in the future to include training courses to certify new users on best practices using this transformational technology.”
“With the opening of our 5th Annual Mass Cytometry Summit on June 10, we are pleased to share this new announcement with the mass cytometry community,” said Pete Betzelos, Senior Vice President of Global Marketing at Fluidigm. “We look forward to sharing the power of mass cytometry with the larger research community to advance the understanding of complex human diseases.”
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for growth markets, such as single-cell biology and production genomics. We sell to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology, and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs, while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@Fluidigm), Facebook page (https://www.facebook.com/Fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
For more information, please visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF, and Helios are trademarks or registered trademarks of Fluidigm Corporation.
Contact: Michaeline Bunting Sr. Director, Marketing Fluidigm Corporation 650 737 4190 email@example.com